Fibroblast growth factor-2 (FGF2) exerts paracrine and autocrine functions on endothelial cells. FGF2-overexpressing murine aortic endothelial cells (FGF2-T-MAE cells) induce opportunistic hemangioendothelioma-like tumors when inoculated in immunode®cient mice. To evaluate the impact of FGF2-mediated activation on gene expression pro®le in transformed endothelial cells, we performed subtractive suppression hybridization analysis between FGF2-T-MAE cells and parental MAE cells. The two cell populations were compared for dierential gene expression also by gene macroarray hybridization with 32 P-labeled cDNAs. The two approaches allowed the identi®cation of 27 transcripts whose expression was upregulated by FGF2 in endothelial cells. With the exception of one unknown gene, the dierentially expressed transcripts encoded for proteins involved in the modulation of cell cycle, dierentiation, and cell adhesion. Among them, the stress-inducible genes A170, GADD45 and GADD153 are upregulated by FGF2 transfection or recombinant growth factor treatment. Their expression was also induced in vascular tumors originated by parental or FGF2-transfected MAE cells in nude mice. This study extends the number of genes involved in tumor angiogenesis and/or endothelial cell transformation, a ®nding with possible implications for the discovery of novel targets for angiostatic therapy.
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Keywords: angiogenesis; endothelium; FGF; gene expression; vascular tumor Angiogenesis is characterized by increased microvessel endothelial cell proliferation, production and/or activation of matrix degrading enzymes, migration in the subendothelial matrix, and dierentiation into functional new blood capillaries (Risau, 1997) . The local, uncontrolled release of angiogenic growth factors and/ or alterations of the production of natural angiogenic inhibitors, with a consequent alteration of the angiogenic balance (Hanahan and Folkman, 1996) , are thought to be responsible for the uncontrolled endothelial cell proliferation that takes place during tumor neovascularization and in several angioproliferative diseases, including diabetic retinopathy, arthritis, Kaposi's sarcoma, and vascular tumors (Enzinger and Weiss, 1995; Folkman, 1995) . Thus, the identi®ca-tion of selective targets in angiogenic and/or transformed endothelium may have signi®cant implications for the development of anti-angiogenic therapies and for the treatment of vascular tumors, including Kaposi's sarcoma. In the last decade several targets for anti-angiogenic therapy have been discovered leading to the development of angiostatic compounds; some of them, including inhibitors of a v b 3 integrin and of the vascular endothelial growth factor (VEGF) signaling pathway, are currently under test in clinical trials (for a review see Liekens et al., 2001a) . In this contest, gene expression pro®les have been described for endothelial cells activated in vitro (Glienke et al., 2000; Kahn et al., 2000; Roland et al., 2000; Wang et al., 2000) or in vivo during tumor angiogenesis (St Croix et al., 2000) . The results have allowed the identi®cation of several known and unknown gene transcripts upregulated in endothelial cells under these conditions. FGF2 was one of the ®rst angiogenic factors to be characterized and implicated in blood vessel growth in dierent physiological and pathological conditions (Klagsbrun and Baird, 1991) . FGF2 may exert its eects on endothelial cells via a paracrine mode consequent to their release by tumor and stromal cells and/or by mobilization from the extracellular matrix. FGF2 may also play an autocrine role in endothelium, leading to the deregulation of endothelial cell behavior (Gualandris et al., 1996) . Accordingly, FGF2 has been implicated in the pathogenesis of lesions of endothelial cell origin, including Kaposi's sarcoma (Ensoli et al., 1994a, b) and hemangiomas (Takahashi et al., 1994) .
Mouse aortic endothelial (MAE) cells express undetectable levels of FGF2 (Ribatti et al., 1999) . We generated FGF2-overexpressing pZipFGF2 MAE cells by stable transfection of parental MAE cells with a retroviral expression vector harboring a human FGF2 cDNA (Gualandris et al., 1996) . Transfectants are characterized by a transformed morphology, increased saturation density, and an invasive and morphogenic (Liekens et al., 2001b) were grown in DMEM supplemented with 10% fetal calf serum in the absence or in the presence of 500 mg/ml of G418 sulfate antibiotic (Life Technologies). Approximately 2610 8 subcon¯uent cells grown in complete medium were used for poly (A) + RNA extraction using FastTrack 1 2.0 kit (Invitrogen) following manufacturer's instructions. Forward SSH (subtraction of FGF-T-MAE/MAE) and reverse SSH (subtraction of MAE/FGF-T-MAE) were performed with 2 mg poly(A) + mRNA from the two cell populations, using the PCR-Select TM cDNA Subtraction Kit (Clontech) according to manufacturer's instructions. PCR products from the secondary PCR of the forward subtracted SSH were directly ligated into pGEM 1 -T vector, using pGEM 1 -T vector System II (Promega) and transformed into DH5-competent E. coli cells. Bacteria were plated on ampicillin-containing agar plates, incubated overnight, and clones with cDNA inserts were identi®ed by a white-blue screening using X-Gal solution and 0.1 M isopropyl-1-thio-b-D-galactoside. Ninety-®ve clones and one blue colony (empty vector) were randomly chosen and arrayed onto a nylon membrane (GeneScreen, NEN) using a dot blot device (Life Technologies). This process was repeated to prepare four identical copies of each blot. Two nylon membranes were hybridized with radio-labelled a- P-labeled cDNA probes (10 6 c.p.m./ml hybridization solution) were added to the hybridization solution (ExpressHyb, Clontech) and the membranes incubated overnight at 688C. The membranes were washed four times for 20 min with 26SSC, 0.5% sodium dodecyl sulphate (SDS) at 688C and twice with 0.26SSC, 0.5% SDS at 688C. Autoradiography was performed using a phospho-imaging system behavior in three-dimensional gels. In vivo, they induce hemangiomas in the chick embryo and opportunistic vascular lesions in nude mice (Gualandris et al., 1996; Ribatti et al., 1999) . A FGF2-overexpressing subclone (FGF2-T-MAE cells) was isolated from these lesions: it retained several of the in vitro properties of pZipFGF2-MAE cells but showed an higher tumorigenic capacity when re-injected in nude mice (Liekens et al., 2001b) . Thus, FGF2-T-MAE cells may represent an unique model in which FGF2-driven gene expression leads to a transformed, highly tumorigenic phenotype in endothelial cells. This model may help to elucidate the molecular determinants of endothelial cell activation during angiogenesis and vascular tumor progression.
To gain a molecular understanding of FGF2-triggered endothelial cell transformation, we compared the gene expression pro®les between exponentially growing tumorigenic FGF2-T-MAE cells and parental MAE cells by subtractive suppression hybridization (SSH). Subtracted PCR products were ligated into a prokaryotic cloning vector and transformed into competent E. coli cells. Ninety-®ve randomly picked clones were arrayed on nylon membranes. Hybridization of the ®lters with 32 P-labeled subtracted cDNAs showed 58 positive spots. To con®rm their putative dierential expression, poly(A) + RNAs from MAE and FGF-T-MAE cells were run in a formaldehydeagarose gel, blotted on membrane, and hybridized with the inserts of the 58 clones. Filters were scanned with a phospho-imager analyser (FLA2000, Fuji), the signal intensities were normalized for expression of both GAPDH and b-actin mRNAs, and compared by computerized image analysis. Among the 58 clones, 21 transcripts showed an increased expression in FGF2-T-MAE versus MAE cells and were then sequenced. The results are summarized in Figure 1 . Out of the 21 clones, ®ve transcripts were present in duplicate, one of them encoding for the LTR sequence derived from the FGF2 retroviral expression vector. Thus, 15 murine genes were found to be upregulated in FGF2-T-MAE cells by the SSH approach. Among them, one encodes for a transcript of unknown function with 100% homology with murine EST AA791500. The other transcripts encode for proteins involved in various cell functions, including cell proliferation, stress response, cell adhesion, and cytoskeleton organization (Figure 1) . In a second set of experiments, 48 newly analysed clones were found to encode for genes already identi®ed during the ®rst screening, thus indicating the exhaustion of the subtracted library.
On this basis, in an attempt to detect additional dierentially expressed genes, we analysed the same poly(A) + RNAs derived from MAE and FGF2-T-MAE cells by gene macroarray hybridization. To this purpose, reverse transcribed poly(A) + RNAs were 32 Plabeled and hybridized to Atlas TM Human 1.2 and Atlas TM Human Cancer 1.2 gene arrays (Clontech). With this alternative approach we were able to identify 12 additional genes that were overexpressed in FGF2-T-MAE cells when compared to parental cells ( Figure  2 and Table 1 ). All the murine transcripts identi®ed by gene array hybridization show a nucleotide identity higher than 80% compared to their human counterpart. Taken together, SSH and gene macro-array approaches allowed the identi®cation of 27 transcripts whose expression was upregulated in FGF2-transformed endothelial cells when compared to normal cells (Table 2) .
FGF2-T-MAE cells represent a subclone originated after in vivo selection of FGF2-overexpressing pZipFGF2-MAE cells. To con®rm that the gene expression pro®le identi®ed in FGF2-T-MAE cells is driven by FGF2 and does not merely re¯ect subclonal heterogeneity, the expression of randomly selected transcripts identi®ed by SSH (A170 and High Mobility Group (HMG)-I) and by gene array hybridization (Growth Arrested DNA Damage (GADD)45 and GADD153) were investigated in parental MAE, pZipFGF2-MAE, and FGF2-T-MAE cells by Northern blotting. As shown in Figure 3A , the expression of the four genes tested was upregulated in both pZipFGF2-MAE and FGF2-T-MAE cells when compared to MAE cells. Also, Western blot analysis of the cell extracts con®rmed that GADD45 and GADD153 upregulation was paralleled by a signi®cant increase in the levels of the corresponding proteins (data not shown).
FGF2-overexpressing MAE cells release limited amounts of FGF2 that are responsible for the alterations in the biological behavior of these cells via an extracellular mechanism of autocrine stimulation (Ribatti et al., 1999) . On this basis, we evaluated the capacity of exogenous recombinant FGF2 to modulate HMG-I, A170, GADD45 and GADD153 mRNA levels in MAE cells. As illustrated in Figure 3B , recombinant FGF2 increases the levels of all the transcripts tested with similar kinetics, a signi®cant stimulation being observed after 6 h of treatment.
(FLA2000, Fuji). Clones hybridizing with cDNA from the forward subtracted library were considered dierentially expressed and listed in the ®rst column. 2.5 micrograms of poly(A) + RNA were separated by denaturing 1.2% agarose gel electrophoresis and transferred to nylon membrane using a TurboBlotter TM apparatus (Schleicher and Schuell). To obtain speci®c probes, 200 ng of plasmid DNA was subjected to 25 cycles of PCR reaction using nested primers provided with PCR-Select TM cDNA subtraction kit (Clontech); the reaction mixture was loaded on agarose gel and, after electrophoresis, the ampli®ed products were isolated using Ultrafree 1 -DNA (Millipore). The recovered DNA was labeled with [a-32 P]dCTP using Ready-to-Go DNA labeling kit (Amersham Pharmacia Biotech). The hybridization procedure was the same described above and the results are shown in the second column. The cDNA inserts of dierentially expressed clones were partially sequenced using DYEnamic Direct Cycle Sequencing kit (Amersham Pharmacia Biotech) exploiting the T7 promoter contained in pGEM 1 -T vector. Sequences were read with Applied Biosystems automated DNA sequencer and compared to GenBank. Homology or identity for each clone was determined based on the highest score using Advanced Blast 2.0 (Altschul and Lipman, 1990) and reported in the third and fourth columns pZipFGF2-MAE cells cause the rapid growth of opportunistic vascular tumors when injected in nude mice (Gualandris et al., 1996) . In contrast, parental MAE cells are poorly tumorigenic, giving raise to highly dierentiated, slow growing hemangiomas (Bastaki et al., 1997) . To validate the involvement of candidate genes in endothelial cell transformation and angiogenesis, we performed semi-quantitative reverse transcribed-PCR analysis of pZipFGF2-MAE and MAE xenografts. As shown in Figure 4A , all genes were upregulated in MAE tumors (lane 3) when compared to in vitro cultured cells (lane 1), possibly re¯ecting the presence of various endogenous cytokines, including FGF2, in tumor microenvironment. The expression of A170, GADD45 and GADD153 genes was further increased in pZipFGF2-MAE xenografts (lane 4), similar to their in vitro counterpart (lane 2).
Finally, newly formed blood vessels invading FGF2-Matrigel plugs implanted s.c. in Balb/c mice were positive for GADD45 immunostaining ( Figure 4B ), further supporting the involvement of this protein in endothelial cell activation during angiogenesis.
FGF2 interaction with non-signaling low anity heparan sulphate proteoglycans is required for high anity interaction with tyrosine-kinase FGF receptors (FGFRs; Klagsbrun and Baird, 1991) . FGFR occupancy and autophosphorylation leads to the activation of various intracellular signal transduction pathways (for a review see Klint and Claesson-Welsh, 1999) . In pZipFGF2-MAE cells, FGF2 accumulates intracellularly and is released in limited amounts in conditioned medium (Ribatti et al., 1999) . The released growth factor can interact with upregulated FGFRs (Table 1) present on the endothelial cell surface, thus activating the classical Ras/Raf-1/MEK/ERK pathway cascade (Besser et al., 1995) . Indeed, a constitutive increase in ERK 1/2 phosphorylation is observed in FGF2-T-MAE cells when compared to parental cells (data not shown). This can regulate the activity of dierent transcription factors including c-Myc, c-Fos, c-Jun and HMG-box proteins (Treisman, 1996) . Both Fos and Myc proteins are essential for taking cells through the cell cycle at the G 1 /S border. Accordingly, we have identi®ed c-jun, fos related antigen-1 (Fra-1), and the c-myc-induced genes prothymosine-a and HMG-I as dierentially expressed in 
arrays (Clontech). A typical result is reported in (A) and (B). Two regions of the ®lters are shown at higher magni®cation in (C) and (D).
Detected genes are (from top to bottom): cytokeratin-6A, -7, and -8, vimentin (slightly upregulated in FGF2-T-MAE cells), and desmin (panels 1a and 1b); cytosolic superoxide-dismutase, GADD45, and GADD153 (panels 2a and/or 2b) (2), and FGF2-T-MAE (3) cells were washed twice with ice-cold PBS and RNA was extracted following the method described by Chomczynski and Sacchi (1987) . (B) Exponentially growing MAE cells (7) were stimulated with 30 ng/ml of recombinant FGF2. RNA was extracted at dierent time points as indicated. In each lane, 20 mg of total RNA were run on formaldehyde-agarose gel and analysed by Northern blotting, using the indicated probes ) were injected s.c. in nude mice. Animals were sacri®ced when lesions had reached an averaged size equal to 0.5 cm 3 (at 5 and 25 weeks for pZipFGF2-MAE and MAE xenografts, respectively) and tumors were snap frozen in liquid nitrogen. Total RNAs (2 mg) extracted from MAE (3) and pZipFGF2-MAE (4) lesions and from subcon¯uent MAE (1) and pZipFGF2-MAE (2) cell cultures were retro-transcribed and 1/10th of the reaction were analysed by PCR using the following primers: A170, forward: TCGTTCACGGTGA-AGGCCTAT; reverse: AGTCCCCATCCTCATCGCGGTAGTG. HMG-I, forward: GAGTCGGGGCTATTTCTGGTG; reverse: GCTCTTTCTGACTCCCGACCAGCG. GADD45, forward: CA-ACGTAGACCCCGATAACGTG; reverse: GTGGGGAGTGA-CTGCTTGAGTAAC. GADD153, forward: CTGAAAGCAGAA-CCTGGTCCAC; reverse: GATGCCCACTGTTCATGCTTG. Tubulin, forward: TCACTGTCCTGAACTTACC; reverse GGAA-CATAGCCGTAAACTGC. (B) Matrigel plugs containing 500 ng/ ml of FGF2 were implanted s.c. in Balb/c mice. After 5 days plugs were embedded in OCT compound, frozen, and 5-mm sections were sequentially incubated with anti-GADD45 antibody, biotinylated secondary antibody, and avidin-biotin-peroxidase complex with no counterstaining. Arrowheads point to GADD45-positive blood vessels antisense construct abrogates transformation in Burkitt's lymphoma cells (Wood et al., 2000) . This suggests that their up-regulation may contribute to the capacity of FGF2-T-MAE xenografts to generate opportunistic vascular tumors (Liekens et al., 2001b) .
Inhibitor of dierentiation-3 (Id3) mRNA is upregulated in FGF2-T-MAE cells. Id proteins block the expression of muscle-speci®c genes. Indeed Id3 binds to ITF-2b, thus inhibiting ITF-2b/MyoD-mediated transcription . Consistent with its role as an inhibitor of dierentiation, Id3 mRNA has been detected in proliferating skeletal muscle cells, is further induced by FGF2, and is down-regulated in dierentiated muscle cell cultures . Recently, Id3 has been shown to be required also for neurogenesis, angiogenesis, and tumor xenograft vascularization (Lyden et al., 1999) . Id3 is expressed in endothelial cells during development and Id3 7/7 mice show vascular malformations and absence of blood vessel sprouting and branching (Lyden et al., 1999) . Our data indicate for the ®rst time that Id3 expression is regulated by an angiogenic growth factor in endothelial cells. Further experiments are required to de®ne the role of this protein during neovascularization and vascular tumor progression.
Modulation of cell movement, invasion, and cell adhesion characterizes the angiogenesis process. This is paralleled by profound changes in cytoskeleton organization of the endothelial cell and in its ability to interact with the substratum. Accordingly, several cytoskeleton components are up-regulated in FGF2-T-MAE cells, including dynein light chain, actin capping protein a2, thymosin-b10, and the intermediate ®lament proteins lamin C and vimentin. Interestingly, we have identi®ed the murine homologue to human centaurin g3 as upregulated in FGF2 transfectants. Centaurins, downstream mediators of phosphoinositide 3-kinase signaling cascades, have been proposed as involved in actin cytoskeletal organization (Jackson et al., 2000) . Also, FGF2-T-MAE cells express high levels of collagen a2 type I and of the a 3 integrin receptor. Some of the identi®ed genes have already been shown to be regulated in endothelial cells by FGF2, like integrin a 3 (Klein et al., 1993) and vimentin (Carey and Zehner, 1995) , or by VEGF (thymosin b10, Vasile et al., 2001) . Also, the study of gene expression pro®les during angiogenesis in vitro and in vivo has identi®ed several cytoskeletal components, as well as extracellular matrix components and their receptors, as upregulated in activated endothelial cells (Glienke et al., 2000; Kahn et al., 2000; St Croix et al., 2000; Wang et al., 2000) . Relevant to this point is the observation that various angiogenesis inhibitors may exert their angiostatic activity by interacting with cytoskeleton (e.g. combretastatin, taxol, and endostatin) or by aecting integrin activity (e.g. cyclic RGD peptides and anti-a v b 3 integrin antibodies) (for a review see Liekens et al., 2001a) .
Defender against cell death 1 (Dad1) gene is upregulated in FGF2-T-MAE cells. It encodes a mammalian oligosaccharyltransferase subunit with anti-apoptotic functions (Kelleher and Gilmore, 1997) . Mice lacking Dad1 express abnormal N-linked glycoproteins and undergo increased embryonic apoptosis paralleled by poor mesoderm development (Hong et al., 2000) . Relevant to this point, FGF-mediated signalling is required for mesodermal patterning during gastrulation (Yamaguchi et al., 1994) .
Interestingly, some of the FGF2-upregulated genes identi®ed in this paper have been described previously as stress-inducible genes, including macrophage migration inhibitory factor (MIF), A170, GADD45 and GADD153 (Table 2) . MIF is a cytokine that mediates host in¯ammatory and immune responses (for a review see Nishihira, 2000) and is up-regulated by transforming growth factor-b, PDGF, and FGF2 (Takahashi et al., 1998) . Recently, immunoneutralization of MIF has been shown to inhibit tumor growth possibly by inhibiting endothelial cell proliferation (Ogawa et al., 2000) . A170 was originally cloned as an oxidative stress-inducible gene (Ishii et al., 1996) . A170 protein contains a Zinc ®nger domain, two PEST sequences, and several potential phosphorylation sites for serine/threonine kinases. It has 90% homology with a human p62 protein that binds to the tyrosine kinase p56 (lck) SH2 domain, is induced by Nrf2 transcription factor (Ishii et al., 2000) , and is phosphorylated by casein kinase II (Yanagawa et al., 1997) . The meaning of FGF2-mediated induction of this gene has to be further evaluated. The two GADD genes are typically induced in response to DNA damaging agents. p53 upregulates GADD45 that blocks cell cycle entry and acts in concert with GADD153 to induce growth arrest (Zhan et al., 1994) . We have observed that upregulation of A170, GADD45 and GADD153 transcripts is not limited to FGF2-transfected endothelial cells but is observed also in normal MAE cells treated with the recombinant growth factor. Accordingly, A170, GADD45 and GADD153 transcripts are highly expressed in vascular tumors originated by MAE and pZipFGF2-MAE cells. Moreover, FGF2-mediated GADDs induction occurs also at the protein level as con®rmed by Western blot analysis of the cell extracts and by immunostaining of newly formed blood vessels in s.c. FGF2-Matrigel plugs. In apparent contrast with these ®ndings, FGF2-T-MAE cells show a high proliferation rate (M Belleri, unpublished observation) and FGF2 induces DNA synthesis when administered to MAE cell cultures (Bastaki et al., 1997) . Clearly, these observations point to a complex interplay among growth arresting genes and proto-oncogenes following FGF2 stimulation in endothelial cells.
FGF2 can be induced by hypoxia (Kuwabara et al., 1995) and promotes angiogenesis under hypoxic conditions (Kuwabara et al., 1995; Kroon et al., 2001) . Interestingly, some of the FGF2-responsive genes that we have identi®ed are upregulated in endothelium also by hypoxic conditions. They include vimentin, enolase a and prothymosin a (Roland et al., 2000) . Moreover, VEGF expression can be induced by FGF2 as well as by hypoxia (Seghezzi et al., 1998; Shweiki et al., 1992) . Thus, both stimuli appear to share, at least in part, common gene activation pathways in promoting angiogenesis.
In conclusion, our data extend the molecular ®ngerprint of the transcriptional pro®le of endothelial cells following activation by an angiogenic factor. Although some of the genes identi®ed in the present work were already known to be involved in the angiogenesis process, other dierentially expressed genes were unexpected. The understanding of their biological signi®cance in endothelial cell activation may help to identify novel potential targets for angiostatic therapy.
